Boy in Singapore Compensated for Heart Attack Linked to Pfizer’s COVID Biologic
Singapore’s Ministry of Health (MOH) announced on Aug. 16, 2021 that it had awarded S$225,000 (just over $165,000) to the family of a 16-year-old boy in Singapore who suffered a heart attack six days after receiving the first dose of Pfizer/BioNTech’s experimental messenger RNA (mRNA) COVID-19 biologic (also known as BNT162b2 or “Comirnaty” vaccine) on June 27.1 2 3 4 5 6 7
The teen reportedly collapsed at his home on the morning of July 3 after returning from the gym where he had been lifting weights. He was taken to Khoo Teck Puat Hospital (KTPH) in the town of Yishun. He was subsequently transferred to the National University Hospital (NUH). Following a medical investigation into the case, the MOH confirmed that the boy had developed acute severe myocarditis
(inflammation of the heart muscle) that health officials said “likely” caused the heart attack.1 2 3 4 5 6 7The MOH stated:
The myocarditis was likely a serious adverse event arising from the COVID-19 vaccine he received, which might have been aggravated by his strenuous lifting of weights and his high consumption of caffeine through energy drinks and supplements.1 3
Compensation Granted Under Vaccine Injury Financial Assistance Program
The financial award was made under the MOH’s Vaccine Injury Financial Assistance Program (VIFAP) and will go to help cover the victim’s medical costs.8 The MOH noted that an independent clinical panel assigned to “assess and adjudicate” the VIFAP application for the case determined that the boy’s cardiac condition was “severe and critical” and that he would “require treatment and rehabilitation for some time yet to continue his recovery.”1 3 8
According to the MOH website:
VIFAP provides one-time goodwill financial assistance to all Singaporean citizens, permanent residents and long-term pass holders vaccinated under the national vaccination program who had experienced serious side effects that are assessed to be related to COVID-19 vaccines.8
Myocarditis Linked to Pfizer, Moderna COVID Biologics in U.S.
In June, the U.S. Food and Drug Administration (FDA) added warning labels to both Pfizer/BioNTech biologic and Moderna/NIAID’s mRNA-1273 biologic after determining a “likely link” between these pharmaceutical products, commonly referred to as vaccines, and cases of myocarditis in the United States. On Aug. 20, The Washington Post reported that U.S. health officials are reviewing reports that the mRNA-1273 product may be linked to a higher risk of myocarditis in younger adults than previously thought.9 10
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References:
No comments:
Post a Comment